Attached files

file filename
EX-31.2 - EXHIBIT 31.2 - INTERCEPT PHARMACEUTICALS, INC.v456571_exh31x2.htm
EX-31.1 - EXHIBIT 31.1 - INTERCEPT PHARMACEUTICALS, INC.v456571_exhx31x1.htm
EX-23.1 - EXHIBIT 23.1 - INTERCEPT PHARMACEUTICALS, INC.v456571_exhx23x1.htm
EX-21.1 - EXHIBIT 21.1 - INTERCEPT PHARMACEUTICALS, INC.v456571_exhx21x1.htm
EX-12.1 - EXHIBIT 12.1 - INTERCEPT PHARMACEUTICALS, INC.v456571_ex12-1.htm
EX-10.18 - EXHIBIT 10.18 - INTERCEPT PHARMACEUTICALS, INC.v456571_ex10-18.htm
EX-10.17 - EXHIBIT 10.17 - INTERCEPT PHARMACEUTICALS, INC.v456571_ex10-17.htm
EX-10.11 - EXHIBIT 10.11 - INTERCEPT PHARMACEUTICALS, INC.v456571_ex10-11.htm
10-K - 10-K - INTERCEPT PHARMACEUTICALS, INC.v456571_10k.htm

Exhibit 32

CERTIFICATIONS UNDER SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intercept Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Annual Report for the year ended December 31, 2016 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
Dated: March 1, 2017   /s/ Mark Pruzanski

Mark Pruzanski, M.D.
President and Chief Executive Officer
(Principal Executive Officer)
Dated: March 1, 2017   /s/ Sandip Kapadia

Sandip Kapadia
Chief Financial Officer
(Principal Financial and Accounting Officer)